Year: 2014
Type: article
Abstract: to have independent validation of the established biomarker results.In this respect, it still remains to be seen whether the 5 prioritized biomarkers from Kubiczkova et al. 5 can be confirmed in an independent cohort.The models or gene signatures from biomarker studies easily suffer from being over fit, as typically many more genes are measured than samples.In these circumstances, multiple hypothesis-testing correction measures need to be taken (e.g.checking for the false discovery rate), along with internal cross-validation or preferably external blinded validation.Furthermore, challenging the novel biomarker in a multi-variate analysis along with established diagnostic markers or risk predictors is also crucial in order to establish the added value of the new marker; if not, it's JAM (just another marker)!Only when a biomarker test has withstood the challenge of independent multi-variate validation will it have a chance of actually being used in the clinic and providing benefits for the patients.And that is the ultimate goal of this type of work.Despite the cautionary notes outlined here, there is a bright future for using circulating RNAs, and in particular microRNAs, because of their tissue specificity and stability, as an embodiment of the long-searched for "Holy Grail" of non-invasive molecular diagnostics.
Source: Haematologica
Authors: M. Bender, H. Falet
Institutions: Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2163577291